Fig. 1: Data on humoral and cellular responses after anti-SARS-CoV-2 vaccine in 64 patients with hematological malignancies who underwent autologous stem cell transplantation. | Bone Marrow Transplantation

Fig. 1: Data on humoral and cellular responses after anti-SARS-CoV-2 vaccine in 64 patients with hematological malignancies who underwent autologous stem cell transplantation.

From: Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

Fig. 1

a Seroconversion rates according to type of disease and type of last therapy. b Association between Ab titer’s GMC and type of last therapy. c FACS and ELISpot analyses of spike-specific T-cell responses according to serological status. ASCT: autologous stem cell transplantation; GMC: geometric mean concentration; NEG: seronegative after vaccination; POS: seropositive after vaccination; FSC/SSC: forward scatter/side scatter; SFC: spot-forming cells; PBMC: peripheral blood mononuclear cells. Immunotherapy includes monoclonal anti-CD38, monoclonal anti-CD20, and bispecific antibodies. Novel agents include immunomodulatory drugs and proteasome inhibitors. Other includes allogeneic stem cell transplantation, chemotherapy, and supportive therapy. *Active therapy was defined as ongoing therapy or therapy discontinued within 6 months from vaccination. In the ELISpot figure: blue rhombi: seropositive patients with low Ab titer; blue circles: seropositive patients with high Ab titer.

Back to article page